Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of Billiontoone stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. Following the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at $100,000. This represents a 90.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total transaction of $2,045,400.00.

Billiontoone Price Performance

NASDAQ:BLLN opened at $95.15 on Friday. The business’s 50-day simple moving average is $115.34 and its two-hundred day simple moving average is $95.29. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44. The stock has a market cap of $4.49 billion and a PE ratio of 135.93.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. As a group, analysts forecast that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BLLN has been the topic of several recent analyst reports. Guggenheim assumed coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price target on the stock. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. reduced their target price on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, BTIG Research lowered their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and an average target price of $126.71.

Institutional Trading of Billiontoone

A number of hedge funds have recently added to or reduced their stakes in BLLN. Rossby Financial LCC purchased a new position in Billiontoone during the 4th quarter valued at about $25,000. Wells Fargo & Company MN purchased a new stake in shares of Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC purchased a new stake in shares of Billiontoone in the 4th quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Billiontoone during the fourth quarter valued at approximately $82,000. Finally, Thrive Wealth Management LLC purchased a new position in Billiontoone during the second quarter valued at approximately $240,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.